2 not yet recruiting, 2 recruiting, 1 completed, 1 unknown. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Not yet recruiting 2, Recruiting 2, Completed 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Random Allocation: new trials by email Literature Review of Random Allocation trials Research Report on Random Allocation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI Ferric Carboxymaltose Injection [Ferinject], Randomization, Questionnaire and Physical Exam - Restless Legs Syndrome (RLS) | Phase 2 | Not yet recruiting | University Hospital, Montpellier | 66 | 2026-10-01 | 2026-09-16 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants ICF, Eligibility Assessment, Demographic data - HIV, HIV Infection | Phase 2 | Recruiting | Code Pharma | 40 | 2023-07-20 | 2024-11-06 |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC BPF-CCRT (run-in), BPF-CCRT (randomized), PF-CCRT (randomized) - Stage III Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | National Taiwan University Hospital | 50 | 2016-06-01 | 2019-03-11 |
Acquired Immunodeficiency Syndrome (1) · Carcinoid Tumor (1) · Carcinoid Tumors, Intestinal (1) · Esophageal Squamous Cell Carcinoma (1) · HIV Infections (1) · Neuroendocrine Tumors (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Restless Legs Syndrome (1) · Serotonin Syndrome (1)
Assistance Publique - Hôpitaux de Paris (1) · Code Pharma (1) · Crinetics Pharmaceuticals Inc. (1) · Evopoint Biosciences Inc. (1) · National Taiwan University Hospital (1) · University Hospital, Montpellier (1)
Brazil (2) · France (2) · Argentina (1) · Canada (1) · Mexico (1) · Peru (1) · Poland (1) · Taiwan (1) · United States (1)